Jaqueline Scholz , Luana D. Portela , Tania Maria Ogawa Abe , Patricia Viviane Gaya , Valter G. Santos , Cristina Ferreira , Clarice Amorim , Alexandre Costa Pereira , Paulo Caleb Junior Lima Santos
{"title":"Cost-effectiveness analysis of smoking-cessation treatment using electronic medical records in a cardiovascular hospital","authors":"Jaqueline Scholz , Luana D. Portela , Tania Maria Ogawa Abe , Patricia Viviane Gaya , Valter G. Santos , Cristina Ferreira , Clarice Amorim , Alexandre Costa Pereira , Paulo Caleb Junior Lima Santos","doi":"10.1016/j.ctrsc.2016.01.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>Evaluating the cost-effectiveness of a first-line smoking cessation drug using an electronic medical record system is very important for defining the best decision-making tree to use in the Brazilian National Health System (SUS). This study aimed to evaluate the cost effectiveness of varenicline compared with bupropion and nicotine replacement therapy (NRT) (gum and patches) in a smoking cessation program.</p></div><div><h3>Methods</h3><p>We included 940 patients admitted to a smoking cessation program. Smokers had access to medical consultations and prescription of nicotine replacement therapies (NRT — patch and gum), bupropion, and varenicline. Incremental cost-effectiveness ratios (ICERs) were estimated in the perspective of the Brazilian Public Health System (SUS).</p></div><div><h3>Results</h3><p>We were able to show that the best cost-effectiveness for one participant to quit smoking was BRL R$ 1.546,40 with varenicline plus bupropion BRL R$ 1.650,00 with varenicline alone; BRL R$ 1.971,32 with bupropion plus gum; BRL R$ 2.413,81 with bupropion plus NRT; and BRL R$ 2.414,26 with NRT alone.</p></div><div><h3>Conclusion</h3><p>Treatment with varenicline showed to be dominant and cost saving compared to NRT and/or bupropion.</p></div>","PeriodicalId":91232,"journal":{"name":"Clinical trials and regulatory science in cardiology","volume":"14 ","pages":"Pages 1-3"},"PeriodicalIF":0.0000,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ctrsc.2016.01.006","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical trials and regulatory science in cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405587516300063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Purpose
Evaluating the cost-effectiveness of a first-line smoking cessation drug using an electronic medical record system is very important for defining the best decision-making tree to use in the Brazilian National Health System (SUS). This study aimed to evaluate the cost effectiveness of varenicline compared with bupropion and nicotine replacement therapy (NRT) (gum and patches) in a smoking cessation program.
Methods
We included 940 patients admitted to a smoking cessation program. Smokers had access to medical consultations and prescription of nicotine replacement therapies (NRT — patch and gum), bupropion, and varenicline. Incremental cost-effectiveness ratios (ICERs) were estimated in the perspective of the Brazilian Public Health System (SUS).
Results
We were able to show that the best cost-effectiveness for one participant to quit smoking was BRL R$ 1.546,40 with varenicline plus bupropion BRL R$ 1.650,00 with varenicline alone; BRL R$ 1.971,32 with bupropion plus gum; BRL R$ 2.413,81 with bupropion plus NRT; and BRL R$ 2.414,26 with NRT alone.
Conclusion
Treatment with varenicline showed to be dominant and cost saving compared to NRT and/or bupropion.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
